Afamelanotide holds promise as a preventative pharmaceutical treatment, improving quality of life for patients with advanced stage bile duct cancer, who are eligible to undergo Photodynamic Therapy (PDT).
CLINUVEL is committed to caring for patients who do not receive medical attention for light and UV related diseases.
We believe strongly in prevention and we are aware of the importance of quality of life.
In 1993 the US NCI provided the seed funding to research a molecule for the prevention of skin cancer.
CLINUVEL spent 9 years to commercially develop this molecule into a viable preventative product to treat severe light and UV related skin disorders.
Through study of preventative applications we have uncovered afamelanotide's potential as a treatment for cancer patients undergoing PDT.
In PDT, similar phototoxic reactions are observed in patients, as the skin reactions seen in Erythropoietic Protoporphyria (EPP). EPP is one of the foci of CLINUVEL Pharmaceuticals.